Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $985.98 | 16 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $186.83 | 2 | $0 (2023) |
| Horizon Therapeutics plc | $139.89 | 2 | $0 (2023) |
| ABBVIE INC. | $132.16 | 2 | $0 (2023) |
| BeiGene USA, Inc. | $122.14 | 1 | $0 (2021) |
| Lilly USA, LLC | $120.89 | 1 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $108.75 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $84.65 | 2 | $0 (2023) |
| Eisai Inc. | $58.24 | 3 | $0 (2024) |
| Octapharma USA, Inc. | $16.66 | 1 | $0 (2023) |
| Grifols USA, LLC | $15.77 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $179.13 | 4 | Lilly USA, LLC ($120.89) |
| 2023 | $555.17 | 8 | Horizon Therapeutics plc ($122.55) |
| 2022 | $129.54 | 3 | Biogen, Inc. ($91.42) |
| 2021 | $122.14 | 1 | BeiGene USA, Inc. ($122.14) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $120.89 | General |
| Category: Neuroscience | ||||||
| 08/22/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Neurology | ||||||
| 04/06/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Neurology | ||||||
| 10/24/2023 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $108.75 | General |
| Category: Dermatology | ||||||
| 10/07/2023 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $70.61 | General |
| Category: IMMUNOLOGY | ||||||
| 07/27/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: TEPEZZA | ||||||
| 07/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $14.04 | General |
| 06/28/2023 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $111.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/01/2023 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Immunology and Neurology | ||||||
| 02/08/2023 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $95.41 | General |
| Category: Neurology | ||||||
| 11/16/2022 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: TEPEZZA | ||||||
| 11/08/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/25/2022 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $91.42 | General |
| Category: Neurology | ||||||
| 10/13/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $122.14 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 598 | 31,484 | $1.1M | $418,513 |
| 2021 | 3 | 194 | 407 | $268,379 | $25,640 |
| 2020 | 2 | 175 | 375 | $267,908 | $19,973 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 138 | 8,340 | $336,744 | $158,294 | 47.0% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 42 | 12,780 | $377,845 | $118,067 | 31.2% |
| J2182 | Injection, mepolizumab, 1 mg | Office | 2023 | 22 | 3,300 | $189,642 | $77,651 | 40.9% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 20 | 6,510 | $122,123 | $52,610 | 43.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 54 | 80 | $13,571 | $4,071 | 30.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 260 | 338 | $11,395 | $3,573 | 31.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 21 | 24 | $8,483 | $2,456 | 29.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 14 | 64 | $3,230 | $1,020 | 31.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 20 | $1,501 | $432.39 | 28.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 28 | $1,064 | $337.96 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 151 | 354 | $118,504 | $23,057 | 19.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 27 | 35 | $8,305 | $1,623 | 19.5% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 16 | 18 | $141,570 | $960.12 | 0.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 156 | 355 | $110,608 | $18,873 | 17.1% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 19 | 20 | $157,300 | $1,100 | 0.7% |
About Chandra Shaw
Chandra Shaw is a Nurse Practitioner healthcare provider based in Thornton, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2019. The National Provider Identifier (NPI) number assigned to this provider is 1689221459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Chandra Shaw has received a total of $985.98 in payments from pharmaceutical and medical device companies, with $179.13 received in 2024. These payments were reported across 16 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($985.98).
As a Medicare-enrolled provider, Shaw has provided services to 967 Medicare beneficiaries, totaling 32,266 services with total Medicare billing of $464,126. Data is available for 3 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Nurse Practitioner
- Other Specialties Nurse Practitioner, Acute Care
- Location Thornton, CO
- Active Since 08/26/2019
- Last Updated 03/08/2024
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1689221459
Products in Payments
- TEPEZZA (Drug) $139.89
- DALVANCE (Drug) $132.16
- BRUKINSA (Drug) $122.14
- KISUNLA (Drug) $120.89
- ILUMYA (Biological) $108.75
- VUMERITY (Drug) $95.41
- TYSABRI (Biological) $91.42
- CUVITRU (Biological) $70.61
- Leqembi (Drug) $58.24
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $16.66
- Gamunex-C (Biological) $15.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Thornton
Tiffany Lanford, Fnp, FNP
Nurse Practitioner — Payments: $6,385
Melanie Ellers, Crnp, CRNP
Nurse Practitioner — Payments: $5,837
Maryem Kianinejad, Np, NP
Nurse Practitioner — Payments: $3,748
Mr. Gerard Bernales, Rn, Msn, Fnp-C, RN, MSN, FNP-C
Nurse Practitioner — Payments: $1,833
Daniel Ramirez, Np-C, NP-C
Nurse Practitioner — Payments: $1,807
Margaret Kreutzer, Fnp-C, FNP-C
Nurse Practitioner — Payments: $1,020